Overview

PT-141 (bremelanotide) is a melanocortin receptor agonist FDA-approved for hypoactive sexual desire disorder (HSDD) in premenopausal women. Also used off-label for male sexual dysfunction.

Mechanism of Action

MC4R agonism — Activates melanocortin-4 receptors in the CNS
Dopamine pathway — Modulates sexual arousal circuits in the brain
Non-hormonal — Does not affect sex hormone levels
Central action — Works on the nervous system, not vascular system (unlike PDE5 inhibitors)

Dosing Protocols

| Use | Dose | Timing | Route | |-----|------|--------|-------| | HSDD (FDA-approved) | 1.75mg | 45 min before activity | Subcutaneous | | Off-label male | 1-2mg | 45-60 min before activity | Subcutaneous | | Max frequency | — | Once daily max, 8 doses/month | — |

Safety Profile

FDA-approved. Common side effects: nausea (40%), flushing, headache, injection site reactions. Contraindicated with uncontrolled hypertension or known cardiovascular disease.